Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines
Pertussis is an acute respiratory disease caused by . Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedul...
Saved in:
| Published in | Frontiers in immunology Vol. 10; p. 1344 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
03.07.2019
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Pertussis is an acute respiratory disease caused by
. Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedule was associated with a marked reduction in pertussis cases in the vaccinated cohort. However, due to the frequency of local and systemic adverse events after immunization with wPV, work on a less reactive vaccine was undertaken based on isolated
components that induced protective immune responses with fewer local and systemic reactions. These component vaccines were termed acellular vaccines and contained one or more pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up to five components were developed, and several efficacy trials clearly demonstrated that the aPVs were able to confer comparable short-term protection than the most effective wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis observed in recent years. This paper reports the results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders (WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence. |
|---|---|
| AbstractList | Pertussis is an acute respiratory disease caused by
Bordetella pertussis
. Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedule was associated with a marked reduction in pertussis cases in the vaccinated cohort. However, due to the frequency of local and systemic adverse events after immunization with wPV, work on a less reactive vaccine was undertaken based on isolated
B. pertussis
components that induced protective immune responses with fewer local and systemic reactions. These component vaccines were termed acellular vaccines and contained one or more pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up to five components were developed, and several efficacy trials clearly demonstrated that the aPVs were able to confer comparable short-term protection than the most effective wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis observed in recent years. This paper reports the results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders (WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence. Pertussis is an acute respiratory disease caused by Bordetella pertussis. Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedule was associated with a marked reduction in pertussis cases in the vaccinated cohort. However, due to the frequency of local and systemic adverse events after immunization with wPV, work on a less reactive vaccine was undertaken based on isolated B. pertussis components that induced protective immune responses with fewer local and systemic reactions. These component vaccines were termed acellular vaccines and contained one or more pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up to five components were developed, and several efficacy trials clearly demonstrated that the aPVs were able to confer comparable short-term protection than the most effective wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis observed in recent years. This paper reports the results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders (WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence.Pertussis is an acute respiratory disease caused by Bordetella pertussis. Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedule was associated with a marked reduction in pertussis cases in the vaccinated cohort. However, due to the frequency of local and systemic adverse events after immunization with wPV, work on a less reactive vaccine was undertaken based on isolated B. pertussis components that induced protective immune responses with fewer local and systemic reactions. These component vaccines were termed acellular vaccines and contained one or more pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up to five components were developed, and several efficacy trials clearly demonstrated that the aPVs were able to confer comparable short-term protection than the most effective wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis observed in recent years. This paper reports the results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders (WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence. Pertussis is an acute respiratory disease caused by Bordetella pertussis. Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedule was associated with a marked reduction in pertussis cases in the vaccinated cohort. However, due to the frequency of local and systemic adverse events after immunization with wPV, work on a less reactive vaccine was undertaken based on isolated B. pertussis components that induced protective immune responses with fewer local and systemic reactions. These component vaccines were termed acellular vaccines and contained one or more pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up to five components were developed, and several efficacy trials clearly demonstrated that the aPVs were able to confer comparable short-term protection than the most effective wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis observed in recent years. This paper reports the results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders (WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence. Pertussis is an acute respiratory disease caused by . Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedule was associated with a marked reduction in pertussis cases in the vaccinated cohort. However, due to the frequency of local and systemic adverse events after immunization with wPV, work on a less reactive vaccine was undertaken based on isolated components that induced protective immune responses with fewer local and systemic reactions. These component vaccines were termed acellular vaccines and contained one or more pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up to five components were developed, and several efficacy trials clearly demonstrated that the aPVs were able to confer comparable short-term protection than the most effective wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis observed in recent years. This paper reports the results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders (WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence. |
| Author | Fedele, Giorgio Knuf, Markus Stefanelli, Paola Paterson, Pauline Rodrigo, Carlos O'Ryan, Miguel Tan, Tina Weil Olivier, Catherine Fry, Norman K He, Qiushui Lutsar, Iria Hung, Ivan Edwards, Kathryn Flanagan, Katie L Principi, Nicola Esposito, Susanna |
| AuthorAffiliation | 11 School of Medicine-Germans Trias i Pujol University Hospita, Universidad Autónoma de Barcelona , Barcelona , Spain 12 Retired, Neuilly-sur-Seine , France 7 Division of Pediatric Infectious Diseases, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago , Chicago, IL , United States 9 Department of Pediatrics, University Medicine , Mainz , Germany 3 Immunisation and Countermeasures Division, Public Health England–National Infection Service , London , United Kingdom 19 Microbiology and Mycology Program, Faculty of Medicine, Institute of Immunology and Immunotherapy, University of Chile , Santiago , Chile 14 School of Health and Biomedical Science, RMIT University , Melbourne, VIC , Australia 16 Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong , Hong Kong , China 8 Children's Hospital, Helios HSk , Wiesbaden , Germany 10 Department of Pediatrics, Vall d'Hebron University Hospital , Barcelon |
| AuthorAffiliation_xml | – name: 9 Department of Pediatrics, University Medicine , Mainz , Germany – name: 4 Institute of Biomedicine, University of Turku , Turku , Finland – name: 14 School of Health and Biomedical Science, RMIT University , Melbourne, VIC , Australia – name: 7 Division of Pediatric Infectious Diseases, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago , Chicago, IL , United States – name: 16 Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong , Hong Kong , China – name: 17 Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu , Tartu , Estonia – name: 1 Department of Surgical and Biomedical Sciences, Paediatric Clinic, Università degli Studi di Perugia , Perugia , Italy – name: 3 Immunisation and Countermeasures Division, Public Health England–National Infection Service , London , United Kingdom – name: 19 Microbiology and Mycology Program, Faculty of Medicine, Institute of Immunology and Immunotherapy, University of Chile , Santiago , Chile – name: 8 Children's Hospital, Helios HSk , Wiesbaden , Germany – name: 10 Department of Pediatrics, Vall d'Hebron University Hospital , Barcelona , Spain – name: 12 Retired, Neuilly-sur-Seine , France – name: 6 Department of Infectious Disease Epidemiology, The Vaccine Confidence Project TM, London School of Hygiene & Tropical Medicine , London , United Kingdom – name: 20 Retired, Milan , Italy – name: 13 School of Medicine, College of Health and Medicine, University of Tasmania , Hobart, TAS , Australia – name: 2 Department of Infectious Diseases, Istituto Superiore di Sanità , Rome , Italy – name: 5 Department of Medical Microbiology, Capital Medical University , Beijing , China – name: 11 School of Medicine-Germans Trias i Pujol University Hospita, Universidad Autónoma de Barcelona , Barcelona , Spain – name: 15 Department of Immunology and Pathology, Monash University , Melbourne, VIC , Australia – name: 18 Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, TN , United States |
| Author_xml | – sequence: 1 givenname: Susanna surname: Esposito fullname: Esposito, Susanna organization: Department of Surgical and Biomedical Sciences, Paediatric Clinic, Università degli Studi di Perugia, Perugia, Italy – sequence: 2 givenname: Paola surname: Stefanelli fullname: Stefanelli, Paola organization: Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy – sequence: 3 givenname: Norman K surname: Fry fullname: Fry, Norman K organization: Immunisation and Countermeasures Division, Public Health England-National Infection Service, London, United Kingdom – sequence: 4 givenname: Giorgio surname: Fedele fullname: Fedele, Giorgio organization: Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy – sequence: 5 givenname: Qiushui surname: He fullname: He, Qiushui organization: Department of Medical Microbiology, Capital Medical University, Beijing, China – sequence: 6 givenname: Pauline surname: Paterson fullname: Paterson, Pauline organization: Department of Infectious Disease Epidemiology, The Vaccine Confidence Project TM, London School of Hygiene & Tropical Medicine, London, United Kingdom – sequence: 7 givenname: Tina surname: Tan fullname: Tan, Tina organization: Division of Pediatric Infectious Diseases, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, United States – sequence: 8 givenname: Markus surname: Knuf fullname: Knuf, Markus organization: Department of Pediatrics, University Medicine, Mainz, Germany – sequence: 9 givenname: Carlos surname: Rodrigo fullname: Rodrigo, Carlos organization: School of Medicine-Germans Trias i Pujol University Hospita, Universidad Autónoma de Barcelona, Barcelona, Spain – sequence: 10 givenname: Catherine surname: Weil Olivier fullname: Weil Olivier, Catherine organization: Retired, Neuilly-sur-Seine, France – sequence: 11 givenname: Katie L surname: Flanagan fullname: Flanagan, Katie L organization: Department of Immunology and Pathology, Monash University, Melbourne, VIC, Australia – sequence: 12 givenname: Ivan surname: Hung fullname: Hung, Ivan organization: Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China – sequence: 13 givenname: Iria surname: Lutsar fullname: Lutsar, Iria organization: Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia – sequence: 14 givenname: Kathryn surname: Edwards fullname: Edwards, Kathryn organization: Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, United States – sequence: 15 givenname: Miguel surname: O'Ryan fullname: O'Ryan, Miguel organization: Microbiology and Mycology Program, Faculty of Medicine, Institute of Immunology and Immunotherapy, University of Chile, Santiago, Chile – sequence: 16 givenname: Nicola surname: Principi fullname: Principi, Nicola organization: Retired, Milan, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31333640$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkU1v1DAQhiNUREvpnRPykUN38XdiDkjVAm2lSlQIuFr-GG9dJXaxk0r8e5LdUlpf5vV45vHY7-vmIOUETfOW4DVjnfoQ4jBMa4qJWmPCOH_RHBEp-YpRyg-e6MPmpNZbPC-uGGPiVXPIyCwkx0dNvIYyTrXGiq4L3EMaY04f0XcwNaeKQi6zrlPZQnJwikzy6HMMAcqyrygmNN4A2kxlTozozEHfT70p6D_2l3EuJqhvmpfB9BVOHuJx8_Prlx-bi9XVt_PLzdnVynFJx5W1RnmPsZQhtIpyiTumJHSqbb3qVHC2ba0Dp8Ab55XnrrMCBDVGBKsEZsfN5Z7rs7nVdyUOpvzR2US9S-Sy1aaM0fWgIQgIC77FjENnrWWC8DYQZkD4ls-sT3vW3WQH8G5-YzH9M-jzkxRv9DbfaymJJFTNgPcPgJJ_T1BHPcS6fJJJkKeqKZWcEikEm0vxvtSVXGuB8HgNwXoxXO8M14vhemf43PLu6XiPDf_sZX8BaBasNQ |
| CitedBy_id | crossref_primary_10_1088_1361_6528_ac56f3 crossref_primary_10_3389_fcimb_2021_797491 crossref_primary_10_3390_ijerph192114082 crossref_primary_10_1016_j_jiph_2023_05_028 crossref_primary_10_35366_115480 crossref_primary_10_12688_wellcomeopenres_16767_1 crossref_primary_10_1016_j_ijantimicag_2023_106835 crossref_primary_10_1017_S0950268820002800 crossref_primary_10_1016_j_vaccine_2020_01_074 crossref_primary_10_3390_ijms242417313 crossref_primary_10_1080_21645515_2023_2253585 crossref_primary_10_1016_j_vaccine_2021_12_004 crossref_primary_10_1080_21645515_2020_1791617 crossref_primary_10_1097_QAD_0000000000003758 crossref_primary_10_1016_j_chom_2023_06_015 crossref_primary_10_1016_j_heliyon_2021_e08386 crossref_primary_10_1007_s12098_022_04384_w crossref_primary_10_7717_peerj_11902 crossref_primary_10_3389_fped_2021_666848 crossref_primary_10_1080_22221751_2023_2239945 crossref_primary_10_1016_j_intimp_2022_109265 crossref_primary_10_3389_fimmu_2023_1124695 crossref_primary_10_3389_fped_2022_850912 crossref_primary_10_1016_j_eclinm_2021_100976 crossref_primary_10_1016_j_eimc_2021_04_009 crossref_primary_10_1016_j_eimce_2021_04_009 crossref_primary_10_1172_jci_insight_157034 crossref_primary_10_7189_jogh_11_08010 crossref_primary_10_1080_14760584_2023_2280236 crossref_primary_10_1016_j_ogc_2023_02_013 crossref_primary_10_1111_epi_17794 crossref_primary_10_4081_jphr_2021_2588 crossref_primary_10_1093_femsle_fnac047 crossref_primary_10_1155_2020_8202067 crossref_primary_10_3390_toxins14030187 crossref_primary_10_1007_s00210_024_03247_9 crossref_primary_10_1007_s40121_021_00440_8 crossref_primary_10_1016_j_meegid_2021_104970 crossref_primary_10_3390_vaccines8030429 crossref_primary_10_3390_vaccines9080877 crossref_primary_10_1007_s00284_022_03009_x crossref_primary_10_1016_j_vaccine_2022_04_038 crossref_primary_10_1016_j_vaccine_2023_11_042 crossref_primary_10_3389_fimmu_2021_662218 crossref_primary_10_1080_14760584_2021_1899823 crossref_primary_10_3201_eid2701_191541 crossref_primary_10_3389_fimmu_2021_711565 crossref_primary_10_3390_life11020171 crossref_primary_10_1007_s10096_022_04453_0 crossref_primary_10_1016_j_vaccine_2020_02_054 crossref_primary_10_3390_toxins16010036 crossref_primary_10_31631_2073_3046_2024_23_1_4_13 crossref_primary_10_3390_vaccines7040168 crossref_primary_10_1016_j_ijantimicag_2020_106258 crossref_primary_10_3201_eid2703_202314 crossref_primary_10_1080_15412555_2023_2169120 crossref_primary_10_3390_vaccines9060637 crossref_primary_10_3389_fmicb_2020_02108 crossref_primary_10_1007_s12519_024_00821_2 crossref_primary_10_1016_j_vaccine_2020_12_062 crossref_primary_10_1007_s40121_023_00876_0 crossref_primary_10_3390_pathogens11070794 crossref_primary_10_1080_14760584_2022_2149499 crossref_primary_10_1186_s12941_021_00458_3 crossref_primary_10_1016_j_vaccine_2023_08_046 crossref_primary_10_1111_mmi_15019 crossref_primary_10_2807_1560_7917_ES_2021_26_37_2001213 crossref_primary_10_1093_femspd_ftad035 crossref_primary_10_1016_j_crmicr_2022_100172 crossref_primary_10_1080_14760584_2021_1990759 crossref_primary_10_3389_fimmu_2020_01282 crossref_primary_10_1016_j_jvacx_2021_100087 crossref_primary_10_1016_S0140_6736_22_02644_7 crossref_primary_10_1016_j_plefa_2022_102452 crossref_primary_10_3390_vaccines11010001 crossref_primary_10_3390_vaccines9030228 crossref_primary_10_1038_s41598_021_89538_0 crossref_primary_10_22625_2072_6732_2021_13_3_30_38 crossref_primary_10_3390_vaccines9060542 crossref_primary_10_1016_j_vaccine_2021_02_045 crossref_primary_10_1016_j_ymben_2021_11_013 crossref_primary_10_2147_JAA_S335960 crossref_primary_10_1016_j_ebiom_2021_103612 crossref_primary_10_3390_vaccines8020217 crossref_primary_10_1016_j_vaccine_2021_01_041 crossref_primary_10_1016_j_diagmicrobio_2024_116225 crossref_primary_10_1371_journal_pone_0238932 crossref_primary_10_3390_vaccines10111953 crossref_primary_10_1007_s00134_019_05862_0 crossref_primary_10_1080_14760584_2021_1984891 crossref_primary_10_3390_vaccines12050525 crossref_primary_10_1111_jvh_13602 crossref_primary_10_1016_j_ijid_2019_08_031 crossref_primary_10_1016_j_coi_2023_102355 crossref_primary_10_1128_iai_00440_23 crossref_primary_10_3390_ijms23148027 |
| Cites_doi | 10.3389/fimmu.2018.00051 10.1128/IAI.70.8.4142-4147.2002 10.1021/acs.jproteome.5b00258 10.1056/NEJM199602083340602 10.1503/cmaj.051637 10.1016/j.vaccine.2014.02.005 10.1542/peds.81.6.933 10.1016/S0264-410X(98)00227-8 10.1080/21645515.2018.1480298 10.1111/j.1469-0691.2012.04000.x 10.1128/CVI.00641-13 10.2307/4592424 10.1073/pnas.1314688110 10.1001/jama.2012.6364 10.1016/j.vaccine.2013.08.034 10.1016/j.vaccine.2010.09.050 10.1128/CVI.00367-12 10.1586/erv.09.88 10.1016/j.vaccine.2009.08.052 10.1099/13500872-145-8-2069 10.1093/femspd/ftv079 10.1128/mBio.01074-14 10.1016/j.vaccine.2003.07.018 10.1016/S0264-410X(98)00226-6 10.1016/j.vaccine.2014.01.081 10.1016/S1473-3099(18)30646-7 10.1093/femspd/ftv064 10.1136/bmj.296.6622.612 10.1093/infdis/jis178 10.1093/cid/ciu788 10.3201/eid2304.161575 10.1016/j.tim.2012.03.003 10.3201/eid2006.131069 10.1016/0264-410X(92)90002-2 10.1016/S0140-6736(97)04334-1 10.1016/j.vaccine.2015.01.063 10.1097/01.inf.0000160914.59160.41 10.3389/fimmu.2018.03068 10.1111/j.1365-2249.2006.03097.x 10.1136/bmj.g3668 10.1016/j.vaccine.2011.05.094 10.1016/j.vaccine.2013.10.056 10.1016/j.jinf.2015.11.004 10.1371/journal.ppat.1000647 10.1016/S0140-6736(94)90485-5 10.1016/S0140-6736(97)06508-2 10.1080/22221751.2018.1564630 10.1371/journal.pone.0077165 10.1542/peds.2015-3973 10.1007/s10096-014-2297-2 10.1371/journal.ppat.1003264 10.1016/S1474-4422(06)70446-X 10.1586/14737159.6.6.857 10.1542/peds.2012-3836 10.1097/INF.0b013e31818a8958 10.1111/j.1469-0691.2012.03925.x 10.1093/infdis/jiu665 10.1016/j.meegid.2012.01.001 10.1038/mi.2012.54 10.1016/j.vaccine.2017.11.066 10.1111/j.1365-2222.2009.03207.x 10.1016/j.vaccine.2014.09.068 10.1016/j.vaccine.2015.09.064 10.2807/1560-7917.ES2014.19.33.20881 10.1016/S1473-3099(17)30390-0 10.3201/eid1508.081511 10.1016/j.vaccine.2009.07.074 10.3201/eid1903.121475 10.1016/S0140-6736(95)92343-8 10.1016/S0099-1767(97)90076-3 10.5694/mja13.10044 10.1056/NEJM199602083340609 10.1371/journal.pone.0031985 10.1016/j.vaccine.2011.02.070 10.1056/NEJM199510193331604 10.1093/cid/cis302 10.1542/peds.2014-1729 10.1371/journal.pone.0197970 10.1038/s41385-018-0080-x 10.1093/infdis/169.6.1297 10.1099/jmm.0.000607 10.1172/JCI121309 10.1016/S0140-6736(84)90061-8 10.1586/14760584.2014.942641 10.1128/CVI.00277-12 10.1542/peds.2010-0887 10.1016/S0264-410X(03)00407-9 10.1128/IAI.46.2.415-421.1984 10.1016/0264-410X(90)90246-I 10.1097/00006454-198704000-00005 10.1186/1471-2458-11-694 10.1056/NEJM199602083340601 |
| ContentType | Journal Article |
| Copyright | Copyright © 2019 Esposito, Stefanelli, Fry, Fedele, He, Paterson, Tan, Knuf, Rodrigo, Weil Olivier, Flanagan, Hung, Lutsar, Edwards, O'Ryan and Principi. 2019 Esposito, Stefanelli, Fry, Fedele, He, Paterson, Tan, Knuf, Rodrigo, Weil Olivier, Flanagan, Hung, Lutsar, Edwards, O'Ryan and Principi |
| Copyright_xml | – notice: Copyright © 2019 Esposito, Stefanelli, Fry, Fedele, He, Paterson, Tan, Knuf, Rodrigo, Weil Olivier, Flanagan, Hung, Lutsar, Edwards, O'Ryan and Principi. 2019 Esposito, Stefanelli, Fry, Fedele, He, Paterson, Tan, Knuf, Rodrigo, Weil Olivier, Flanagan, Hung, Lutsar, Edwards, O'Ryan and Principi |
| CorporateAuthor | World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG) |
| CorporateAuthor_xml | – name: World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG) |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fimmu.2019.01344 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-3224 |
| ExternalDocumentID | oai_doaj_org_article_ef5ef83967034e8bbb35147f13ae5d74 10_3389_fimmu_2019_01344 31333640 |
| Genre | Journal Article Review |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CGR CUY CVF DIK EBS ECM EIF EMOBN GROUPED_DOAJ GX1 HYE IAO IEA IHR IHW IPNFZ KQ8 M48 M~E NPM OK1 PGMZT RIG RNS RPM AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c462t-bba9dd0066ff7924608396e8977d989fcb77bcec9edacd9d4c8b5e52aa5fb9503 |
| IEDL.DBID | RPM |
| ISSN | 1664-3224 |
| IngestDate | Tue Oct 22 15:15:52 EDT 2024 Tue Sep 17 21:10:44 EDT 2024 Sat Oct 26 02:11:22 EDT 2024 Thu Sep 26 18:24:49 EDT 2024 Sat Nov 02 12:28:50 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | whole-cell pertussis vaccine acellular pertussis vaccine pertussis prevention Bordetella pertussis pertussis |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c462t-bba9dd0066ff7924608396e8977d989fcb77bcec9edacd9d4c8b5e52aa5fb9503 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Edited by: Luciana Leite, Instituto Butantan, Brazil This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology Reviewed by: Camille Locht, Institut National de La Santé et de la Recherche Médicale (INSERM), France; Carmen Alvarez-Dominguez, Instituto de Investigación Marques de valdecilla (IDIVAL), Spain; Kingston H. Mills, Trinity College Dublin, Ireland |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616129/ |
| PMID | 31333640 |
| PQID | 2264216553 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ef5ef83967034e8bbb35147f13ae5d74 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6616129 proquest_miscellaneous_2264216553 crossref_primary_10_3389_fimmu_2019_01344 pubmed_primary_31333640 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-07-03 |
| PublicationDateYYYYMMDD | 2019-07-03 |
| PublicationDate_xml | – month: 07 year: 2019 text: 2019-07-03 day: 03 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in immunology |
| PublicationTitleAlternate | Front Immunol |
| PublicationYear | 2019 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Bouchez (B83) 2009; 27 Larson (B115) 2014; 32 B23 B24 Clarke (B92) 2016; 72 Plotkin (B4) 2013 B29 Belcher (B72) 2015; 73 Clark (B41) 2012; 20 Seubert (B98) 2014; 13 Storsaeter (B64) 1998; 16 B33 Gangarosa (B9) 1998; 351 Miller (B34) 1997; 89 Schure (B61) 2012; 19 van Gent (B73) 2015; 34 (B113) 2013; 62 B1 Esposito (B50) 2018; 14 Taranger (B101) 1994; 344 Lam (B78) 2012; 12 Sheridan (B42) 2012; 308 Palazzo (B100) 2016; 39 Cherry (B3) 1988; 81 Brummelman (B65) 2015; 33 Jajosky (B19) 2006; 53 Wendelboe (B37) 2005; 24 Miyaji (B89) 2013; 8 Broutin (B35) 2004; 22 McNabb (B20) 2007; 54 Storsaeter (B96) 2003; 21 Faulkner (B26) 2011 Smits (B63) 2013; 32 Carollo (B99) 2014; 32 Allen (B53) 2018; 11 Yeung (B2) 2017; 17 Raeven (B55) 2015; 14 Wilk (B54) 2019; 8 Safarchi (B94) 2015; 33 Higgs (B58) 2012; 5 Martin (B85) 2015; 60 Wirsing von König (B36) 1995; 346 Ross (B56) 2013; 9 Okada (B87) 2010; 28 Storsaeter (B11) 1990; 8 Octavia (B79) 2012; 205 Zeddeman (B86) 2014; 19 Wang (B47) 2014; 348 Bart (B71) 2014; 5 Chit (B46) 2018; 13 van der Lee (B66) 2018; 36 McGirr (B45) 2015; 135 Robbins (B95) 2009; 28 Breakwell (B80) 2016; 137 Bodilis (B91) 2013; 19 Adams (B22) 2014; 61 Wearing (B38) 2009; 5 Wendelboe (B25) 2006; 6 Hegerle (B76) 2012; 18 Solans (B52) 2019; 9 B112 Olin (B108) 1997; 350 B110 B111 Kaczmarek (B31) 2013; 198 Esposito (B49) 2001; 69 Hallander (B109) 2014; 21 da Silva Antunes (B68) 2018; 128 Otsuka (B88) 2012; 7 van der Lee (B69) 2018; 9 Hegerle (B93) 2014; 32 Advani (B75) 2011; 29 Thierry-Carstensen (B97) 2013; 31 Knight (B106) 2006; 144 Lambert (B39) 1965; 80 Vickers (B43) 2006; 175 Mastrantonio (B84) 1999; 145 Romanus (B8) 1987; 6 Cherry (B27) 2012; 54 Aalberse (B67) 2009; 39 Berkovic (B5) 2006; 5 Jenkinson (B40) 1988; 296 Hiramatsu (B90) 2017; 23 Warfel (B70) 2014; 111 Adams (B21) 2012; 59 Alonso (B105) 2002; 70 Sealey (B81) 2015; 212 Palazzo (B57) 2016; 39 Gustafsson (B13) 1996; 334 (B114) 2017 Cherry (B107) 1998; 16 Reyes (B6) 2011; 128 McIntyre (B18) 2000; 24 Campbell (B30) 2014; 20 Klein (B44) 2013; 131 Hendrikx (B60) 2009; 27 Trollfors (B10) 1995; 333 Mooi (B74) 2009; 15 Ryan (B59) 1997; 89 Hallander (B15) 2009; 8 Sato (B102) 1984; 46 Kallonen (B77) 2012; 18 Sato (B7) 1984; 1 B16 B17 Marchant (B28) 1994; 169 Periscope (B51) 2019; 19 Scheller (B104) 2015; 73 Barkoff (B82) 2012; 19 Fisman (B32) 2011; 11 Principi (B48) 2017; 66 Greco (B12) 1996; 334 Edwards (B14) 1996; 334 Hendrikx (B62) 2011; 29 Sorsaeter (B103) 1992; 10 |
| References_xml | – volume: 61 start-page: 1 year: 2014 ident: B22 article-title: Summary of notifiable diseases—United States, 2012 publication-title: MMWR Morb Mortal Wkly Rep contributor: fullname: Adams – volume: 9 start-page: 51 year: 2018 ident: B69 article-title: Whole-cell or acellular pertussis primary immunizations in infancy determines adolescent cellular immune profiles publication-title: Front Immunol doi: 10.3389/fimmu.2018.00051 contributor: fullname: van der Lee – volume: 53 start-page: 1 year: 2006 ident: B19 article-title: Summary of notifiable diseases—United States, 2004 publication-title: MMWR Morb Mortal Wkly Rep contributor: fullname: Jajosky – volume: 70 start-page: 4142 year: 2002 ident: B105 article-title: Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role publication-title: Infect Immun doi: 10.1128/IAI.70.8.4142-4147.2002 contributor: fullname: Alonso – ident: B112 – volume: 14 start-page: 2929 year: 2015 ident: B55 article-title: Immunoproteomic profiling of Bordetella pertussis outer membrane vesicle vaccine reveals broad and balanced humoral immunogenicity publication-title: J Proteome Res. doi: 10.1021/acs.jproteome.5b00258 contributor: fullname: Raeven – volume: 334 start-page: 349 year: 1996 ident: B13 article-title: A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine publication-title: N Engl J Med doi: 10.1056/NEJM199602083340602 contributor: fullname: Gustafsson – ident: B29 – volume: 175 start-page: 1213 year: 2006 ident: B43 article-title: Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children publication-title: CMAJ doi: 10.1503/cmaj.051637 contributor: fullname: Vickers – volume: 32 start-page: 2093 year: 2014 ident: B99 article-title: Humoral and B-cell memory responses in children five years after pertussis acellular vaccine priming publication-title: Vaccine. doi: 10.1016/j.vaccine.2014.02.005 contributor: fullname: Carollo – volume: 81 start-page: 933 year: 1988 ident: B3 article-title: Report of the task force on pertussis and pertussis immunization publication-title: Pediatrics doi: 10.1542/peds.81.6.933 contributor: fullname: Cherry – volume: 16 start-page: 1907 year: 1998 ident: B64 article-title: Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis publication-title: Vaccine doi: 10.1016/S0264-410X(98)00227-8 contributor: fullname: Storsaeter – volume: 14 start-page: 2452 year: 2018 ident: B50 article-title: Prevention of pertussis: an unresolved problem publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2018.1480298 contributor: fullname: Esposito – volume: 18 start-page: E377 year: 2012 ident: B77 article-title: Rapid detection of the recently emerged Bordetella pertussis strains with the ptxP3 pertussis toxin promoter allele by real-time PCR publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2012.04000.x contributor: fullname: Kallonen – volume: 21 start-page: 165 year: 2014 ident: B109 article-title: Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007 publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00641-13 contributor: fullname: Hallander – volume: 80 start-page: 365 year: 1965 ident: B39 article-title: Epidemiology of a small pertussis outbreak in Kent county, Michigan publication-title: Public Health Rep doi: 10.2307/4592424 contributor: fullname: Lambert – volume: 111 start-page: 787 year: 2014 ident: B70 article-title: Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1314688110 contributor: fullname: Warfel – volume: 308 start-page: 1432 year: 2012 ident: B42 article-title: Number and order of whole cell pertussis vaccines in infancy and disease protection publication-title: JAMA doi: 10.1001/jama.2012.6364 contributor: fullname: Sheridan – volume: 31 start-page: 5178 year: 2013 ident: B97 article-title: Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults–a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience publication-title: Vaccine. doi: 10.1016/j.vaccine.2013.08.034 contributor: fullname: Thierry-Carstensen – volume: 28 start-page: 7626 year: 2010 ident: B87 article-title: Safe and effective booster immunization using DTaP in teenagers publication-title: Vaccine doi: 10.1016/j.vaccine.2010.09.050 contributor: fullname: Okada – volume: 19 start-page: 1703 year: 2012 ident: B82 article-title: Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00367-12 contributor: fullname: Barkoff – volume: 8 start-page: 1303 year: 2009 ident: B15 article-title: Efficacy and effectiveness of acellular pertussis vaccines: a 20-year Swedish experience publication-title: Expert Rev Vacc. doi: 10.1586/erv.09.88 contributor: fullname: Hallander – volume: 27 start-page: 6530 year: 2009 ident: B60 article-title: IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content publication-title: Vaccine doi: 10.1016/j.vaccine.2009.08.052 contributor: fullname: Hendrikx – volume: 145 start-page: 2069 year: 1999 ident: B84 article-title: Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children publication-title: Microbiology. doi: 10.1099/13500872-145-8-2069 contributor: fullname: Mastrantonio – volume: 73 start-page: ftv079 year: 2015 ident: B104 article-title: Bordetella filamentous hemagglutinin and fimbriae: critical adhesins with unrealized vaccine potential publication-title: Pathog Dis doi: 10.1093/femspd/ftv079 contributor: fullname: Scheller – volume: 5 start-page: e01074 year: 2014 ident: B71 article-title: Global population structure and evolution of Bordetella pertussis and their relationship with vaccination publication-title: MBio doi: 10.1128/mBio.01074-14 contributor: fullname: Bart – ident: B24 – volume: 22 start-page: 594 year: 2004 ident: B35 article-title: Loss of immunity to pertussis in a rural community in Senegal publication-title: Vaccine. doi: 10.1016/j.vaccine.2003.07.018 contributor: fullname: Broutin – volume: 16 start-page: 1901 year: 1998 ident: B107 article-title: A search for serologic correlates of immunity to Bordetella pertussis cough illnesses publication-title: Vaccine. doi: 10.1016/S0264-410X(98)00226-6 contributor: fullname: Cherry – volume: 32 start-page: 2150 year: 2014 ident: B115 article-title: Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012 publication-title: Vaccine. doi: 10.1016/j.vaccine.2014.01.081 contributor: fullname: Larson – volume: 19 start-page: e179 year: 2019 ident: B51 article-title: Periscope: road towards effective control of pertussis publication-title: Lancet Infect Dis. doi: 10.1016/S1473-3099(18)30646-7 contributor: fullname: Periscope – volume: 73 start-page: ftv064 year: 2015 ident: B72 article-title: Bordetella pertussis evolution in the (functional) genomics era publication-title: Pathog Dis. doi: 10.1093/femspd/ftv064 contributor: fullname: Belcher – ident: B17 – volume: 296 start-page: 612 year: 1988 ident: B40 article-title: Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study publication-title: Br Med J doi: 10.1136/bmj.296.6622.612 contributor: fullname: Jenkinson – volume: 205 start-page: 1220 year: 2012 ident: B79 article-title: Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008–2010 publication-title: J Infect Dis doi: 10.1093/infdis/jis178 contributor: fullname: Octavia – volume: 60 start-page: 223 year: 2015 ident: B85 article-title: Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage publication-title: Clin Infect Dis doi: 10.1093/cid/ciu788 contributor: fullname: Martin – volume-title: The Australian Immunisation Handbook. year: 2017 ident: B114 – volume: 23 start-page: 699 year: 2017 ident: B90 article-title: Significant decrease in pertactin-deficient Bordetella pertussis isolates, Japan publication-title: Emerg Infect Dis doi: 10.3201/eid2304.161575 contributor: fullname: Hiramatsu – volume: 20 start-page: 211 year: 2012 ident: B41 article-title: Pertussis control: time for something new? publication-title: Trends Microbiol doi: 10.1016/j.tim.2012.03.003 contributor: fullname: Clark – volume: 62 start-page: 131 year: 2013 ident: B113 article-title: Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women–Advisory Committee on Immunization Practices (ACIP), 2012 publication-title: MMWR Morb Mortal Wkly Rep – volume: 20 start-page: 968 year: 2014 ident: B30 article-title: Oral fluid testing for pertussis, England and Wales, June 2007-August 2009 publication-title: Emerg Infect Dis doi: 10.3201/eid2006.131069 contributor: fullname: Campbell – ident: B110 – ident: B1 – volume: 10 start-page: 142 year: 1992 ident: B103 article-title: Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance publication-title: Vaccine doi: 10.1016/0264-410X(92)90002-2 contributor: fullname: Sorsaeter – volume: 24 start-page: 22 year: 2000 ident: B18 article-title: Vaccine preventable diseases and vaccination coverage in Australia, 1993–1998 publication-title: Commun Dis Intell contributor: fullname: McIntyre – ident: B23 – volume: 351 start-page: 356 year: 1998 ident: B9 article-title: Impact of anti-vaccine movements on pertussis control: the untold story publication-title: Lancet doi: 10.1016/S0140-6736(97)04334-1 contributor: fullname: Gangarosa – volume: 33 start-page: 1483 year: 2015 ident: B65 article-title: Modulation of the CD4(+) T cell response after acellular pertussis vaccination in the presence of TLR4 ligation publication-title: Vaccine. doi: 10.1016/j.vaccine.2015.01.063 contributor: fullname: Brummelman – volume: 24 start-page: S58 year: 2005 ident: B37 article-title: Duration of immunity against pertussis after natural infection or vaccination publication-title: Pediatr Infect Dis J doi: 10.1097/01.inf.0000160914.59160.41 contributor: fullname: Wendelboe – volume: 9 start-page: 3068 year: 2019 ident: B52 article-title: The Role of mucosal immunity in pertussis publication-title: Front Immunol doi: 10.3389/fimmu.2018.03068 contributor: fullname: Solans – volume: 144 start-page: 543 year: 2006 ident: B106 article-title: Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.2006.03097.x contributor: fullname: Knight – volume: 54 start-page: 1 year: 2007 ident: B20 article-title: Summary of notifiable diseases—United States, 2005 publication-title: MMWR Morb Mortal Wkly Rep contributor: fullname: McNabb – volume: 348 start-page: g3668 year: 2014 ident: B47 article-title: Whooping cough in school age children presenting with persistent cough in UK primary care after introduction of the preschool pertussis booster vaccination: prospective cohort study publication-title: BMJ doi: 10.1136/bmj.g3668 contributor: fullname: Wang – volume: 29 start-page: 5725 year: 2011 ident: B62 article-title: Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age publication-title: Vaccine doi: 10.1016/j.vaccine.2011.05.094 contributor: fullname: Hendrikx – volume: 32 start-page: 111 year: 2013 ident: B63 article-title: Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination publication-title: Vaccine doi: 10.1016/j.vaccine.2013.10.056 contributor: fullname: Smits – volume: 72 start-page: 171 year: 2016 ident: B92 article-title: The relationship between Bordetella pertussis genotype and clinical severity in Australian children with pertussis publication-title: J Infect. doi: 10.1016/j.jinf.2015.11.004 contributor: fullname: Clarke – volume: 5 start-page: e1000647 year: 2009 ident: B38 article-title: Estimating the duration of pertussis immunity using epidemiological signatures publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1000647 contributor: fullname: Wearing – volume: 344 start-page: 1703 year: 1994 ident: B101 article-title: Parapertussis infection followed by pertussis infection publication-title: Lancet doi: 10.1016/S0140-6736(94)90485-5 contributor: fullname: Taranger – volume: 350 start-page: 1569 year: 1997 ident: B108 article-title: Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine publication-title: Lancet. doi: 10.1016/S0140-6736(97)06508-2 contributor: fullname: Olin – volume: 8 start-page: 169 year: 2019 ident: B54 article-title: Immunization with whole cell but not acellular pertussis vaccines primes CD4 TRM cells that sustain protective immunity against nasal colonization with Bordetella pertussis publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2018.1564630 contributor: fullname: Wilk – volume: 8 start-page: e77165 year: 2013 ident: B89 article-title: Genetic analysis of Bordetella pertussis isolates from the 2008–2010 pertussis epidemic in Japan publication-title: PLoS ONE. doi: 10.1371/journal.pone.0077165 contributor: fullname: Miyaji – volume-title: Vaccines year: 2013 ident: B4 contributor: fullname: Plotkin – volume: 137 start-page: e20153973 year: 2016 ident: B80 article-title: Pertussis vaccine effectiveness in the setting of pertactin-deficient pertussis publication-title: Pediatrics. doi: 10.1542/peds.2015-3973 contributor: fullname: Breakwell – start-page: 1 volume-title: VPD Surveillance Manual year: 2011 ident: B26 article-title: Pertussis contributor: fullname: Faulkner – volume: 34 start-page: 821 year: 2015 ident: B73 article-title: Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998–2012 publication-title: Eur J Clin Microbiol Infect Dis. doi: 10.1007/s10096-014-2297-2 contributor: fullname: van Gent – volume: 9 start-page: e1003264 year: 2013 ident: B56 article-title: Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1003264 contributor: fullname: Ross – volume: 5 start-page: 488 year: 2006 ident: B5 article-title: De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study publication-title: Lancet Neurol doi: 10.1016/S1474-4422(06)70446-X contributor: fullname: Berkovic – volume: 6 start-page: 857 year: 2006 ident: B25 article-title: Diagnosis of pertussis: a historical review and recent developments publication-title: Expert Rev Mol Diagn doi: 10.1586/14737159.6.6.857 contributor: fullname: Wendelboe – volume: 131 start-page: e1716 year: 2013 ident: B44 article-title: Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers publication-title: Pediatrics doi: 10.1542/peds.2012-3836 contributor: fullname: Klein – volume: 28 start-page: 237 year: 2009 ident: B95 article-title: Pertussis vaccine: a critique publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e31818a8958 contributor: fullname: Robbins – volume: 18 start-page: E340 year: 2012 ident: B76 article-title: Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin publication-title: Clin Microbiol Infect. doi: 10.1111/j.1469-0691.2012.03925.x contributor: fullname: Hegerle – volume: 212 start-page: 294 year: 2015 ident: B81 article-title: Genomic analysis of isolates from the United Kingdom 2012 pertussis outbreak reveals that vaccine antigen genes are unusually fast evolving publication-title: J Infect Dis doi: 10.1093/infdis/jiu665 contributor: fullname: Sealey – ident: B16 – volume: 12 start-page: 492 year: 2012 ident: B78 article-title: Selection and emergence of pertussis toxin promoter ptxP3 allele in the evolution of Bordetella pertussis publication-title: Infect Genet Evol. doi: 10.1016/j.meegid.2012.01.001 contributor: fullname: Lam – volume: 5 start-page: 485 year: 2012 ident: B58 article-title: Immunity to the respiratory pathogen Bordetella pertussis publication-title: Mucosal Immunol doi: 10.1038/mi.2012.54 contributor: fullname: Higgs – volume: 36 start-page: 220 year: 2018 ident: B66 article-title: Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination publication-title: Vaccine doi: 10.1016/j.vaccine.2017.11.066 contributor: fullname: van der Lee – volume: 39 start-page: 469 year: 2009 ident: B67 article-title: Immunoglobulin G4: an odd antibody publication-title: Clin Exp Allergy doi: 10.1111/j.1365-2222.2009.03207.x contributor: fullname: Aalberse – ident: B111 – volume: 32 start-page: 6597 year: 2014 ident: B93 article-title: Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine publication-title: Vaccine. doi: 10.1016/j.vaccine.2014.09.068 contributor: fullname: Hegerle – volume: 33 start-page: 6277 year: 2015 ident: B94 article-title: Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model publication-title: Vaccine. doi: 10.1016/j.vaccine.2015.09.064 contributor: fullname: Safarchi – volume: 19 start-page: 20881 year: 2014 ident: B86 article-title: Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012 publication-title: Euro Surveill doi: 10.2807/1560-7917.ES2014.19.33.20881 contributor: fullname: Zeddeman – volume: 17 start-page: 974 year: 2017 ident: B2 article-title: An update of the global burden of pertussis in children younger than 5 years: a modelling study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(17)30390-0 contributor: fullname: Yeung – volume: 15 start-page: 1206 year: 2009 ident: B74 article-title: Bordetella pertussis strains with increased toxin production associated with pertussis resurgence publication-title: Emerg Infect Dis. doi: 10.3201/eid1508.081511 contributor: fullname: Mooi – volume: 27 start-page: 6034 year: 2009 ident: B83 article-title: First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin publication-title: Vaccine doi: 10.1016/j.vaccine.2009.07.074 contributor: fullname: Bouchez – volume: 19 start-page: 471 year: 2013 ident: B91 article-title: Virulence of pertactin-negative Bordetella pertussis isolates from infants, France publication-title: Emerg Infect Dis doi: 10.3201/eid1903.121475 contributor: fullname: Bodilis – volume: 346 start-page: 1326 year: 1995 ident: B36 article-title: Pertussis in adults: frequency of transmission after household exposure publication-title: Lancet doi: 10.1016/S0140-6736(95)92343-8 contributor: fullname: Wirsing von König – volume: 89 start-page: 15 year: 1997 ident: B34 article-title: Epidemiological determinants of pertussis publication-title: Dev Biol Stand doi: 10.1016/S0099-1767(97)90076-3 contributor: fullname: Miller – volume: 89 start-page: 297 year: 1997 ident: B59 article-title: Bordetella pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: comparison of the T cell cytokine profiles in infants and mice publication-title: Dev Biol Stand contributor: fullname: Ryan – volume: 39 start-page: 35 year: 2016 ident: B57 article-title: Persistence of T-cell immune response induced by two acellular pertussis vaccines in children five years after primary vaccination publication-title: New Microbiol contributor: fullname: Palazzo – volume: 198 start-page: 624 year: 2013 ident: B31 article-title: Sevenfold rise in likelihood of pertussis test requests in a stable set of Australian general practice encounters, 2000–2011 publication-title: Med J Aust doi: 10.5694/mja13.10044 contributor: fullname: Kaczmarek – volume: 334 start-page: 391 year: 1996 ident: B14 article-title: Acellular pertussis vaccines for infants publication-title: N Engl J Med doi: 10.1056/NEJM199602083340609 contributor: fullname: Edwards – volume: 7 start-page: e31985 year: 2012 ident: B88 article-title: Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan publication-title: PLoS ONE. doi: 10.1371/journal.pone.0031985 contributor: fullname: Otsuka – volume: 29 start-page: 3438 year: 2011 ident: B75 article-title: Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs publication-title: Vaccine. doi: 10.1016/j.vaccine.2011.02.070 contributor: fullname: Advani – volume: 59 start-page: 1 year: 2012 ident: B21 article-title: Summary of notifiable diseases—United States, 2010 publication-title: MMWR Morb Mortal Wkly Rep contributor: fullname: Adams – volume: 333 start-page: 1045 year: 1995 ident: B10 article-title: A placebo-controlled trial of a pertussis-toxoid vaccine publication-title: N Engl J Med doi: 10.1056/NEJM199510193331604 contributor: fullname: Trollfors – volume: 54 start-page: 1756 year: 2012 ident: B27 article-title: Clinical definitions of pertussis: summary of a global pertussis initiative roundtable meeting, February 2011 publication-title: Clin Infect Dis doi: 10.1093/cid/cis302 contributor: fullname: Cherry – volume: 135 start-page: 331 year: 2015 ident: B45 article-title: Duration of pertussis immunity after DTaP immunization: a meta-analysis publication-title: Pediatrics doi: 10.1542/peds.2014-1729 contributor: fullname: McGirr – volume: 13 start-page: e0197970 year: 2018 ident: B46 article-title: Acellular pertussis vaccines effectiveness over time: a systematic review, meta-analysis and modeling study publication-title: PLoS ONE. doi: 10.1371/journal.pone.0197970 contributor: fullname: Chit – volume: 11 start-page: 1763 year: 2018 ident: B53 article-title: Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells publication-title: Mucosal Immunol doi: 10.1038/s41385-018-0080-x contributor: fullname: Allen – volume: 169 start-page: 1297 year: 1994 ident: B28 article-title: Pertussis in Massachusetts, 1981–1991: incidence, serologic diagnosis, and vaccine effectiveness publication-title: J Infect Dis doi: 10.1093/infdis/169.6.1297 contributor: fullname: Marchant – ident: B33 – volume: 69 start-page: 4516 year: 2001 ident: B49 article-title: Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection publication-title: Infect Immun doi: 10.1099/jmm.0.000607 contributor: fullname: Esposito – volume: 128 start-page: 3853 year: 2018 ident: B68 article-title: Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters publication-title: J Clin Invest. doi: 10.1172/JCI121309 contributor: fullname: da Silva Antunes – volume: 66 start-page: 1699 year: 2017 ident: B48 article-title: Pertussis-associated persistent cough in previously vaccinated children publication-title: J Med Microbiol doi: 10.1099/jmm.0.000607 contributor: fullname: Principi – volume: 1 start-page: 122 year: 1984 ident: B7 article-title: Development of a pertussis component vaccine in Japan publication-title: Lancet doi: 10.1016/S0140-6736(84)90061-8 contributor: fullname: Sato – volume: 13 start-page: 1191 year: 2014 ident: B98 article-title: Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines publication-title: Expert Rev Vaccines doi: 10.1586/14760584.2014.942641 contributor: fullname: Seubert – volume: 19 start-page: 1879 year: 2012 ident: B61 article-title: T-cell responses before and after the fifth consecutive acellular pertussis vaccination in 4-year-old Dutch children publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00277-12 contributor: fullname: Schure – volume: 128 start-page: e699 year: 2011 ident: B6 article-title: Alleged cases of vaccine encephalopathy rediagnosed years later as Dravet syndrome publication-title: Pediatrics. doi: 10.1542/peds.2010-0887 contributor: fullname: Reyes – volume: 39 start-page: 35 year: 2016 ident: B100 article-title: Persistence of T-cell immune response induced by two acellular pertussis vaccines in children five years after primary vaccination publication-title: New Microbiol contributor: fullname: Palazzo – volume: 21 start-page: 3542 year: 2003 ident: B96 article-title: Low levels of anti-pertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis publication-title: Vaccine. doi: 10.1016/S0264-410X(03)00407-9 contributor: fullname: Storsaeter – volume: 46 start-page: 415 year: 1984 ident: B102 article-title: Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system publication-title: Infect Immun doi: 10.1128/IAI.46.2.415-421.1984 contributor: fullname: Sato – volume: 8 start-page: 457 year: 1990 ident: B11 article-title: Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial publication-title: Vaccine doi: 10.1016/0264-410X(90)90246-I contributor: fullname: Storsaeter – volume: 6 start-page: 364 year: 1987 ident: B8 article-title: Pertussis in Sweden after the cessation of general immunization in 1979 publication-title: Pediatr Infect Dis J doi: 10.1097/00006454-198704000-00005 contributor: fullname: Romanus – volume: 11 start-page: 694 year: 2011 ident: B32 article-title: Pertussis resurgence in Toronto, Canada: a population-based study including test-incidence feedback modeling publication-title: BMC Public Health doi: 10.1186/1471-2458-11-694 contributor: fullname: Fisman – volume: 334 start-page: 341 year: 1996 ident: B12 article-title: A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis doi: 10.1056/NEJM199602083340601 contributor: fullname: Greco |
| SSID | ssj0000493335 |
| Score | 2.5816917 |
| SecondaryResourceType | review_article |
| Snippet | Pertussis is an acute respiratory disease caused by
. Due to its frequency and severity, prevention of pertussis has been considered an important public health... Pertussis is an acute respiratory disease caused by Bordetella pertussis. Due to its frequency and severity, prevention of pertussis has been considered an... Pertussis is an acute respiratory disease caused by Bordetella pertussis . Due to its frequency and severity, prevention of pertussis has been considered an... |
| SourceID | doaj pubmedcentral proquest crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1344 |
| SubjectTerms | acellular pertussis vaccine Bordetella pertussis Bordetella pertussis - immunology Humans Immunology pertussis pertussis prevention Pertussis Vaccine - immunology Pertussis Vaccine - therapeutic use Vaccines, Acellular - immunology Vaccines, Acellular - supply & distribution whole-cell pertussis vaccine Whooping Cough - epidemiology Whooping Cough - immunology Whooping Cough - prevention & control |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Ni9RAEG1kQfAiun5F3aUFL4JxM-mvtLf1Y1kERcSVvTVdnWocYTOymRz231vdnVlnRPDiLSQhaV5V0u8l1a8Ye96hgWRMVpsgYi2B0rjrNJLm0X5hohSQ11d8_KRPz-SHc3W-1eor1YQVe-AC3BFGhZFmcU2pKbEDgFR7buJCeFS9KU6gjd0SUz8K7xVCqPJfklSYPYrLi4splXLZV8R6pNyZh7Jd_9845p-lkltzz8kddnsmjfy4DPYuu4HDPrtZ2khe3WPLz3i5nii5R75xZFoNr_kX9ESmR060lLbHKS-zxJfcDz1_N_dFobcEXw6cWCCfnZr4cfqWn4pT-e_LfvMh_YAf77Ozk_df357WcwuFOkjdrmsAb_s-8YoYDUkt3SQosSPW19vOxgDGQMBgsfeht70MHShUrfcqglWNeMD2htWAjxj3UgtsWmgDMYIGvAetVSD-I4AkYWsr9mIDqPtZnDIcKYwEvsvguwS-y-BX7E1C_Pq85HGdd1Dk3Rx596_IV-zZJl6OnokEjh9wNY0uLQ5uF1opUbGHJX7XtxIkyoWWTcXMTmR3xrJ7ZFh-z77bRGWID9rH_2PwT9itBEcu_BVP2d76csIDojdrOMyZ_Aska_sF priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1baxQxFA62IvhSvLveiOCL4NTdyW0iiNRLKYIi4krfQpI5qSvubN3ZAfvvPScz27qyj30b5hq-k8v3Tc6FsWcVmECJyQoTRSpkwG5cVRpQ82g_MUmKkOMrPn3WR1P58VgdX4RHDwC2W6Ud1ZOaLn_t__l99gYH_GtSnLjevkyz-bwjLy27j4RGyh12tZSo08mRbyD7P3suLIRQ_V7l1gc31qacwn8b7_zfffKf9ejwBtsbiCQ_6C1_k12B5ha71peWPLvNZl9gueqww7d8naVp0bziX8EjwW45UlU8brscegkvuG9q_n6olYIzB581HJkhH7I38QP6v08Oq_zitd99pE359g6bHn749u6oGMoqFFHqclWE4G1dE9dIyaD80sjCrIYKmWBtK5tiMCZEiBZqH2tby1gFBar0XqVg1VjcZbvNooH7jHupBYzLUEZkCePgfdBaReREIqBMLO2IPV8D6k777BkOVQeB7zL4jsB3GfwRe0uIn99Hea_zicXyxA3DyEFSkKi5OFFJqEIIFIlg0kR4ULXBlzxd28vhOCFwfAOLrnUUMFxOtFJixO719jv_lEChLrQcj5jZsOxGWzavNLMfORc30hvkiPbBZTT-IbtOcGRnYPGI7a6WHTxGyrMKT3JP_guC7gMl priority: 102 providerName: Scholars Portal |
| Title | Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31333640 https://www.proquest.com/docview/2264216553 https://pubmed.ncbi.nlm.nih.gov/PMC6616129 https://doaj.org/article/ef5ef83967034e8bbb35147f13ae5d74 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbaSkhcEC2vhVIZiQsS2Ucc2zG30lIqpEUVomhvlu2MSxDrrTabA_-esZOUXcSJixXlac03sb-x50HI6xKkjYnJMumYzwqLalyWAtDmEWYmfcFsiq-YfxaX18WnBV_sET7EwiSnfWfrcfi5HIf6e_KtvF26yeAnNrman-GcghOzmuyTfVTQLRP9R0d5GWO825JEA0xNfL1cttGLS42R8BSxFA9D04yJuOKxNRulpP3_Ypp_O0xuzUAXD8mDnjrS066Lh2QPwhG51xWT_PWI1Few3rSo4g0d8jKtwjv6BQxS6oYiOcXjpk3BlvCWmlDR8746Co4VtA4UuSDt8zXR07iiH11U6Z_XfjMubsM3j8n1xYevZ5dZX0ghc4XIN5m1RlVVZBfeSzS4BPIuJaBE7lepUnlnpbQOnILKuEpVhSstB54bw71VfMqekIOwCvCMUFMIBtPc5g55wdQaY4XgDlkQs2gY5mpE3gwC1bddvgyNdkbEQSccdMRBJxxG5H2U-N19MdN1OrFa3-gebw2eg4_dxaGpgNJaG2MPpJ8xA7yS-JJXA14a_4woHBNg1TY6hgjnM8E5G5GnHX53nxrwHxG5g-xOX3avoDKm7Nu98j3_7ydfkPtRBsnnlx2Tg826hZfIbDb2JK0IYPtxMcN2XpQnSbd_A8Ij_fs |
| link.rule.ids | 230,315,730,783,787,867,888,2109,24330,27936,27937,53804,53806 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKEYIL78LyNBIXJJLdjWMn5lYK1QLdqkJt1ZvlcWwIsNlqkxzg1zN2krJbcYFblIfjeGbsb-JvZgh5mdsMfGKyKDPMRSmgGue5sOjzCD3NXMogxFfMD8XsJP14xs-2CB9iYQJp30AZVz8WcVV-DdzK84UZDzyx8dF8D9cUXJjl-Aq5ivY6Sdec9G8d6GWM8W5TEl0wOXblYtF6HpeMEfKkvhgPQ-eMCf_PY209Cmn7_4Y1L1Mm19ag_VvkdOh9Rz35HrcNxObXpcSO__x5t8nNHpXS3e7yHbJlq7vkWlen8uc9Uh7ZVdOi9dR0SPm0rN7Qz1YjWq8p4l48rtsQx2lfU10V9F1feAWnIVpWFGEm7VNB0V2_WeDZr_RPs6fa-B3--j452X9_vDeL-hoNkUlF0kQAWhaFBy7OZejLCYR0UtgcYWUhc-kMZBkYa6QttClkkZocuOWJ1tyB5BO2Q7arZWUfEqpTwewkgcQg5JiA1iAENwiwGKDPmcgReTVISp13qTgUujBewCoIWHkBqyDgEXnrRXlxn0-iHU4sV19UP9bKOm6d7y7OeqnNAcCHNWRuyrTlRYaNvBgUQaHR-cHRlV22tfLRx8lUcM5G5EGnGBevGhRrRLINldnoy-YVVISQ2LsX_KP_fvI5uT47nh-ogw-Hnx6TG348ArWYPSHbzaq1TxFANfAsmMtvguMdPw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagCMSF92N5GokLEpvsxrETcystq_JotUIUVb1YHseGAJtdbZID_HrGTlJ2K069RYnj2J4ZzzfxPAh5mdsMfGKycWaYG6eAbJznwqLNI_Q0cymDEF9xeCQOjtMPJ_xko9RXcNo3UEbVr0VUld-Db-VqYeLBTyyeH-6hTkHFLONV4eLL5ArK7ERsGOo_OuDLGOPdwSSaYTJ25WLRel8uGSHsSX1BHoYGGhP-v8eGTgqp-_-HN8-7TW7oodlNcjrMoHM_-Rm1DUTmz7nkjhea4i1yo0endLdrcptcstUdcrWrV_n7Linndt20KEU1HVI_Las39LPViNprivgXr-s2xHPa11RXBd3vC7DgdkTLiiLcpH1KKLrrDw28Fyz91-1XbfxJf32PHM_efdk7GPe1GsYmFUkzBtCyKDyAcS5Dm04gtJPC5ggvC5lLZyDLwFgjbaFNIYvU5MAtT7TmDiSfsPtkp1pW9iGhOhXMThJIDEKPCWgNQnCDQIsB2p6JHJFXA7XUqkvJodCU8URWgcjKE1kFIo_IW0_Os3Y-mXa4sVx_U_16K-u4dX64uPulNgcAH96QuSnTlhcZdvJiYAaFwucXR1d22dbKRyEnU8E5G5EHHXOcfWpgrhHJtthmayzbT5AZQoLvnviPLvzmc3Jtvj9Tn94ffXxMrvvlCB7G7AnZadatfYo4qoFnQWL-Alh9H78 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pertussis+Prevention%3A+Reasons+for+Resurgence%2C+and+Differences+in+the+Current+Acellular+Pertussis+Vaccines&rft.jtitle=Frontiers+in+immunology&rft.au=Susanna+Esposito&rft.au=Paola+Stefanelli&rft.au=Norman+K.+Fry&rft.au=Giorgio+Fedele&rft.date=2019-07-03&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=10&rft_id=info:doi/10.3389%2Ffimmu.2019.01344&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_ef5ef83967034e8bbb35147f13ae5d74 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |